Below are our currently enrolling studies for patients with different forms of lupus.
Sponsor: UCB Biopharma SRL
Protocol Number: SL0044
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Detailed Information:
To learn more or see if you qualify: Click Here
Sponsor: Bristol-Myers Squibb
Protocol Number: IM034-1000
The purpose of this study is to evaluate safety, drug levels and drug effects on cells and organs of the body, after receiving multiple increasing doses of BMS-986326 via intravenous (IV) infusion or subcutaneous (SC) injection, in participants with different forms of lupus.
Detailed Information:
To learn more or see if you qualify: Click Here